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Key Points
• Factor IX, but not factor




• Embryonic factor XI,
but not factor IX, pre-
vents enlargement of
blood pools in low-TF
placentas.
The intrinsic tenase complex (FIXa-FVIIIa) of the intrinsic coagulation pathway and, to
a lesser extent, thrombin-mediated activation of FXI, are necessary to amplify tissue factor
(TF)-FVIIa–initiated thrombin generation. In this study, we determined the contribution of
murine FIX and FXI to TF-dependent thrombin generation in vitro. We further investigated
TF-dependent FIX activation in mice and the contribution of this pathway to hemostasis.
Thrombin generation was decreased in FIX- but not in FXI-deficient mouse plasma.
Furthermore, injection of TF increased levels of FIXa-antithrombin complexes in both wild-
type and FXI2/2 mice. Genetic studies were used to determine the effect of complete
deficiencies of either FIX or FXI on the survival of mice expressing low levels of TF. Low-TF;
FIX2/y male mice were born at the expected frequency, but none survived to wean. In
contrast, low-TF;FXI2/2 mice were generated at the expected frequency at wean and had
a 6-month survival equivalent to that of low-TF mice. Surprisingly, a deficiency of FXI, but
not FIX, exacerbated the size of blood pools in low-TF placentas and led to acute hemorrhage
and death of some pregnant dams. Our data indicate that FIX, but not FXI, is essential for
survival of low-TF mice after birth. This finding suggests that TF-FVIIa–mediated activation
of FIX plays a critical role in murine hemostasis. In contrast, FXI deficiency, but not FIX
deficiency, exacerbated blood pooling in low-TF placentas, indicating a tissue-specific
requirement for FXI in the murine placenta under conditions of low TF.
Introduction
The coagulation cascade can be divided into the extrinsic (tissue factor [TF]–factor [F] VIIa complex),
intrinsic (FXIIa, FXIa, FIXa, and FVIIIa), and common (FXa, FVa, and thrombin) pathways.1 The extrinsic
pathway is the physiologic trigger of blood coagulation and activates both FIX and FX.2-4 TF-FVIIa–mediated
activation of FIX was initially described by Francois Josso and colleagues2 and is commonly referred to as
the “Josso loop.” The intrinsic pathway also contains a feedback loop in which thrombin activates FXI
leading to further generation of FIXa.5,6 These pathways are thought to play an importnant role in thrombin
generation, because the TF-FVIIa complex is rapidly inhibited by TF pathway inhibitor (TFPI).7
Humans deficient in FVIII (hemophilia A) or FIX (hemophilia B) have hemostatic defects.8 Sim-
ilarly, FVIII2/2 and FIX2/2 mice exhibit increased bleeding after a hemostatic challenge, such as tail
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transection.9,10 FXI-deficient patients rarely have spontaneous
bleeding events, but increased bleeding occurs in some patients
on provocation, particularly in tissues with high fibrinolytic activity,
such as the mouth, nose, and genitourinary tract.11,12 FXI is thought
to stabilize the fibrin clot and protect it from fibrinolysis.13,14 FXI2/2
mice have normal bleeding times in the tail vein transection model.15
One study reported a significant increase in bleeding in FXI2/2mice
in the saphenous vein injury model,16 but this was not confirmed in
an independent study.17 In vitro studies have shown that FXI
contributes to thrombin generation in human plasma initiated by
low, but not high, concentrations of TF.18-20
In contrast to studies with mice lacking components of the intrinsic
pathway, a complete deficiency of components of the extrinsic or
common pathways in mice leads to death during embryonic
development or shortly after birth.21-28 For instance, 80% to 90%
of TF2/2 embryos die at embryonic day (E) 9.5-E10.5.21-23 TF2/2
mice can be rescued with a transgene that expresses human TF
(hTF) regulated by the human TF promoter.29 These “low-TF” mice
(murine TF2/2 [mTF2/2];hTF1/1) express ;1% levels of TF. Low-
TF mice exhibit spontaneous hemostatic defects in various organs
and have significantlyincreased bleeding in the tail vein transection
model.1,30-32 Mice expressing ;1% levels of FVII have phenotypes
similar to those of low-TF mice.33,34 It is notable that maternal blood
pooling occurs in placentas of low-TF embryos but does not cause
any loss of embryos or fatal hemorrhages in the dams.31 The
placenta is derived from embryonic tissue, indicating that blood
pooling is related to low levels of TF in the embryo.
In the current study, we investigated the contribution of FIX and FXI
to thrombin generation in vitro and in vivo under conditions of low
TF. Plasma-based thrombin generation assays were used to assess
the relative contribution of FIX and FXI to TF-initiated thrombin
generation. The ability of the TF-FVIIa complex to activate FIX in vivo
was also determined in wild-type and FXI2/2 mice. Finally, a genetic
approach was employed to determine the effect of a complete




FIX2/2 and FXI2/2 mice were backcrossed 10 generations to the
C57BL/6J background.10,15 Low-TF mice (mTF2/2;hTF1/1) were
backcrossed 6 generations to the C57BL/6J background.29
Studies complied with National Institutes of Health Guide for the
Care and Use of Laboratory Animals and were performed with the
approval of the Animal Care and Use Committee of the University of
North Carolina at Chapel Hill.
All additional details of experimental procedures are given in the
supplemental Methods.
Results
Effect of either FIX or FXI deficiency on TF-initiated
thrombin generation in murine plasma
The effect of FIX deficiency on TF-initiated thrombin generation in
mouse platelet-poor plasma (PPP) was determined. Endogenous
thrombin potential (ETP), time to peak, peak, and lag time were
measured. As expected, a significant reduction in peak thrombin
generation and ETP was observed in FIX-deficient plasma compared
with control plasma when thrombin generation was initiated with
a low concentration of TF (Figure 1A; data not shown).
Next, the contribution of FXI to thrombin generation was determined
in mouse plasma in which activation of coagulation was initiated by
either silica or TF. As expected, silica-initiated thrombin generation
was significantly impaired in FXI2/2 PPP compared with FXI1/2 or
FXI1/1 PPP (Figure 1B). In contrast, there was no significant
difference in thrombin generation (lag time, time to peak, peak, or
ETP) in FXI2/2 PPP compared with FXI1/1 or FXI1/2 PPP, at
a low concentration of TF (Figure 1C; data not shown). To exclude
the potential effects of contact pathway activation during blood
collection, additional samples were collected in the presence of
corn trypsin inhibitor (CTI). However, even in the presence of CTI,
despite observing a robust reduction in silica-induced thrombin
generation (Figure 1D; data not shown), there was no difference in
TF-initiated thrombin generation between FXI1/1, FXI1/2, or FXI2/2
PPP (Figure 1E; data not shown).
Platelets provide an important surface for the activation of FXI
and may be important in FXI-mediated amplification of thrombin
generation.35-37 To account for the potential effects of platelets
we assessed thrombin generation in platelet-rich plasma (PRP).
When coagulation was initiated with silica, thrombin generation
was significantly reduced in PRP from FXI2/2 mice compared
to FXI1/2 or FXI1/1 controls (Figure 1F). In contrast, when
coagulation was initiated with TF, there was no difference in
thrombin generation in PRP from FXI2/2mice compared to FXI1/2
or FXI1/1 controls (Figure 1G; data not shown). Collectively, these
data in PPP and PRP show that, although FXI deficiency was
detectable in mouse plasma in contact silica-initiated assays, FXI
did not contribute to thrombin generation in mouse plasma when
initiated by TF.
TF activates FIX in vivo in the absence of FXI
To determine whether TF can activate FIX in vivo, mice were injected
with TF and plasma levels of FIXa-antithrombin (AT) complexes
measured. The thrombin inhibitor dabigatran was used to prevent
death associated with the formation of intravascular thrombi after
injection of TF and to block thrombin-mediated activation of FXI.
Injection of TF into wild-type mice significantly increased the plasma
levels of FIXa-AT complexes compared with controls (Figure 2A).
FXI2/2 mice were used to eliminate the thrombin-FXIa feedback
loop. Similar to the results in wild-type mice, TF injection significantly
increased the plasma levels of FIXa-AT complexes in thrombin-
inhibited FXI2/2 mice (Figure 2B). These results indicate that the
TF-FVIIa complex activates FIX in mice.
Effect of FIX deficiency on the survival of
low-TF offspring
The FIX gene resides on the X chromosome. Therefore, to study the
effect of FIX deficiency on low-TF mice, male mTF2/2;hTF1/1;FIX1/y
and female mTF1/2;hTF1/2;FIX1/2 were crossed and the allele
frequencies of offspring determined at various timepoints. No male
low-TF;FIX2/y offspring were observed at postnatal day (P) 21,
a significant reduction compared with the expected frequency
(Table 1). Next, offspring were analyzed at E14.5 to determine if
low-TF;FIX2/y offspring had survived development beyond E9.5
and E10.5 given that embryos lacking various coagulation factors
die at this time point. Viable low-TF;FIX2/y offspring were observed
at E14.5 (Table 1) and appeared grossly normal by histological






































































































Figure 1. Effect of deficiency of FIX or FXI on thrombin
generation in murine plasma. (A) Thrombin generation in murine
FIX-deficient PPP was initiated with low and high concentrations of
hTF. Thrombin generation in mFXI-deficient PPP collected in the ab-
sence of CTI was initiated with silica (B) or low and high doses of
hTF (C). Thrombin generation in mFXI-deficient PPP collected in the
presence of CTI was initiated with silica (D) or low and high doses
of hTF (E). Thrombin generation in mFXI-deficient PRP collected in
the presence of CTI was initiated with silica (F) or low and high
doses of hTF (G). Data are presented as individual values with
means 6 95% confidence intervals. *P , .05, 2-way analysis of var-
iance with post hoc Bonferroni test (FIX1/1 vs FIX2/2); **P , .001,
1-way analysis of variance with post hoc Bonferroni test (FXI1/1
and FXI1/2 vs FXI2/2).
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analysis (data not shown). Finally, the number of low-TF;FIX2/y at
P1 was analyzed. Male low-TF;FIX2/y offspring were observed at
P1 (Table 1). However, 2 of the 5 (40%) male P1 low-TF;FIX2/y
offspring were dead. One low-TF;FIX2/y P1 pup was pale and had
a dark abdomen, which was consistent with abdominal hemor-
rhage (supplemental Figure 1). One of the 6 (17%) male low-TF;
FIX1/y P1 pups was dead with no apparent phenotype. These
results indicate that FIX is essential for postnatal survival of low-
TF mice.
FXI deficiency does not affect the generation or
survival of low-TF offspring
The effect of FXI deficiency on the generation and survival of
mice expressing low levels of TF was determined. Male and female
F1 intermediates (mTF1/2;hTF1/2;FXI1/2) were crossed, and
the allele frequencies of 117 offspring were determined. Six of
117 (5.13%) of the offspring at wean were low TF;FXI2/2, which
was not significantly different from the expected frequency of
4.69% (Table 2). Four additional crosses with sires and dams of
differing genotypes were conducted to yield larger numbers of low-
TF;FXI2/2 offspring. Similar to the results observed when crossing
F1 intermediates low-TF;FXI2/2micewere generated at a frequency
that was not significantly different from the expected frequency
in these 4 additional breedings (supplemental Table 1). These
observations indicate that, even when overall procoagulant potential
is reduced under conditions of low TF, FXI is not necessary for
survival in mice.
Next, the effect of FXI deficiency on the survival of low-TF mice
between weaning and 6 months of age was determined. As
expected from previous studies,38,39 27% (3 of 11) of low-TF;
FXI1/1 mice died during the 6-month survival study, with evidence
of pulmonary hemorrhage in all mice. Importantly, survival did not
differ significantly between low-TF;FXI2/2, low TF;FXI1/2 offspring,
and low-TF;FXI1/1 controls (Figure 3).
Death of pregnant dams bearing low-TF;FXI2/2
embryos
While generating low-TF;FXI2/2 offspring, the death of pregnant
mTF1/2;hTF1/(1/2);FXI1/2 (n 5 6) and mTF1/2;hTF1/(1/2);FXI2/2
(n 5 5) dams bearing low-TF;FXI2/2 embryos occurred during late
gestation (E13.5-15.5) in all 5 breedings (Table 3). In breeding 1, death
occurred in 9% (2 of 33) of pregnancies in mTF1/2;hTF1/(1/2);FXI1/2
dams. Death of 20% to 40% of pregnant mTF1/2;hTF1/(1/2);FXI1/2
dams in breedings 2 and 3 and of 30% to 33% of the pregnant
mTF1/2;hTF1/(1/2);FXI2/2 dams in breedings 4 and 5 was
observed. These results suggest that the death of the pregnant
dams was associated with the relative burden of low-TF;FXI2/2
embryos and was largely independent of the maternal FXI
genotype.
There was a trend toward increased death of the pregnant dams
as the burden of low-TF;FXI2/2 embryos increased (Table 3). To
further investigate whether there was an association between the
frequency of low-TF;FXI2/2 offspring and maternal death, the
burden of low-TF;FXI2/2 offspring was determined for pregnancies
in which the dam survived vs those in which the dam died. Interestingly,
dams that died carried a higher proportion of low-TF;FXI2/2 embryos







































Figure 2. TF activates FIX in thrombin-inhibited wild-type and FXI
2/2
mice.
Plasma levels of FIXa-AT complexes were quantified in dabigatran-pretreated
wild-type (WT) (A) or FXI2/2 (B) mice, administered either vehicle control or TF
(n 5 6-10 per group). A significant increase in plasma FIXa-AT complexes was ob-
served on administration of TF in both WT and FXI2/2 mice. Data are presented as
individual values with means 6 95% confidence intervals. *P , .0001; **P , .05;
unpaired Student t test.
Table 1. Distribution of genotypes at weaning from a breeding to generate low-TF;FIX2/2 offspring
Sex mTF hTF FIX Expected, % E14.5, n E14.5 observed, % E14.5 O/E, % P1, n P1 observed, % P1 O/E, % P21, n P21 observed, % P21 O/E, %
F 1/2 1/(1/2) 1/1 12.5 7 18.4 147 3 6.6 52 15 18.5 148
F 1/2 1/(1/2) 1/2 12.5 7 18.4 147 7 15.5 147 13 16.0 128
M 1/2 1/(1/2) 1/y 12.5 1 2.6 21 10 22.2 178 15 18.5 148
M 1/2 1/(1/2) 2/y 12.5 4 10.5 84 8 17.7 142 9 11.1 89
F 2/2 1/(1/2) 1/1 12.5 5 13.2 106 4 8.8 70 8 9.9 79
F 2/2 1/(1/2) 1/2 12.5 5 13.2 106 2 4.4 35 12 14.8 118
M 2/2 1/(1/2) 1/y 12.5 5 13.2 106 6* 13.3 106 9 11.1 89
M 2/2 1/(1/2) 2/y 12.5 4 10.5 84 5† 11.1 89 0 0 0‡
Total 100.0 38 100.0 — 45 100.0 — 81 100.0 —
F, female; hTF1/(1/2), hTF1/2 or hTF1/1; M, male; O/E, observed/expected.
*One of 6 dead.
†Two of 5 dead.
‡P , .05 observed vs expected, 2-tailed Fisher’s exact test.
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FXI deficiency is associated with increased size of
blood pools in low-TF placentas
Necropsies were conducted on 9 of the 11 dams carrying low-TF;
FXI2/2 embryos that had either died (n5 8) or had been euthanized
due to uterine hemorrhage (n5 1) during late gestation. Free blood
was observed in the uterus of 3 of 9 (33%) of the females that died
with evidence of ruptured low-TF;FXI2/2 placentas, suggesting that
some of the pregnant females carrying low-TF;FXI2/2 embryos died
of acute uterine or placental hemorrhage.
The size of the maternal blood pools in low-TF;FXI2/2 placentas
was compared to those in low-TF;FXI1/2 placentas and low-TF;FXI1/1
placentas removed from dead or euthanized dams (Figure 4A-B).
The average size of the maternal blood pools was significantly
increased in low-TF;FXI2/2 placentas compared with low-TF;
FXI1/1 placentas (Figure 4B). In addition, 5 of 17 low-TF;FXI2/2
placentas appeared to have ruptured (Figure 4B). Of note, FIX
deficiency did not affect the size of the blood pools (Figure 4B).
Importantly, no abnormalities were observed in FXI2/2 placentas
with 50% or 100% levels of mouse TF (Figure 4A).
Given the observation that FXI deficiency exacerbated placental
blood pooling under conditions of low TF, F9, F11, and F12 gene
expression was assessed in wild-type mouse placentas. A high level
of F11 mRNA, but not of F9 or F12 mRNA, was observed in the
placenta (Figure 4C), suggesting that local FXI expression plays
a role in the placenta.
The contribution of FIX-independent functions of FXI in the exacerba-
tion of blood pooling in low-TF placentas was investigated. FXIa has
been shown to proteolytically inactivate TFPI.40 Conversely, FXIa can
proteolytically cleave pro-hepatocyte growth factor (pro-HGF)
to active HGF.41 Therefore, levels of TFPI and pro-HGF were
analyzed in placentas from FXI2/2 and FXI1/1 embryos. If FXIa
were a major proteolytic inactivator of TFPI, increased expression
of full-length TFPI protein would be expected in FXI2/2 placentas.
However, TFPI protein expression in FXI2/2 placentas was signifi-
cantly lower than that in FXI1/1 controls (Figure 4D-E). In contrast,
levels of pro-HGF protein were significantly higher in FXI2/2
placentas than in FXI1/1 controls (Figure 4D, F), suggesting that
FXIa regulates activation of pro-HGF in the placenta.
Discussion
The FIXa;FVIIIa complex has been proposed to sustain activation of
coagulation and thrombin generation after inhibition of the TF-FVIIa
complex by TFPI. Importantly, the TF-FVIIa complex is known to
activate both FIX and FX in vitro.1-3,42 Indeed, an in vitro study
comparing activation of FIX and FX by the TF-FVIIa complex
concluded that FIX is the major substrate.4 In addition, individuals
with a point mutation in FIX that reduces interaction with TF-FVIIa
but not FXI have a mild form of hemophilia B.43 Furthermore, basal
levels of FIXa activation are reduced in FVII-deficient (,7% levels)
but not in FXI-deficient (,8% levels) individuals.44 Taken together,
these in vitro and in vivo studies indicate that the TF-FVIIa complex is
a major activator of FIX.
Consistent with the important contribution of TF-FVIIa–mediated
activation of FIX to thrombin generation, a deficiency of FIX markedly
blunted TF-initiated thrombin generation in human plasma.45-47 A
similar approach has been taken to investigating the contribution
of thrombin-mediated FXI activation to thrombin generation. In
FXI-deficient human plasma, thrombin generation is impaired at
a low, but not a high, initiating concentration of TF.20,48,49 Taken
together, these data suggest that, in humans, TF-FVIIa–mediated
activation of FIX and, to a lesser extent, thrombin-mediated
Table 2. Distribution of genotypes at weaning from a breeding to
generate low-TF;FXI2/2 offspring
mTF hTF FXI Expected, % Observed, n Observed, % O/E, %
1/1 — 1/1 1.56 4 3.42 219
1/1 — 1/2 3.13 4 3.42 109
1/1 — 2/2 1.56 4 3.42 219
1/1 1/(1/2) 1/1 4.69 6 5.13 109
1/1 1/(1/2) 1/2 9.38 10 8.55 91
1/1 1/(1/2) 2/2 4.69 2 1.71 36
1/2 — 1/1 3.13 2 1.71 55
1/2 — 1/2 6.25 8 6.84 109
1/2 — 2/2 3.13 3 2.56 82
1/2 1/(1/2) 1/1 9.38 16 13.68 146
1/2 1/(1/2) 1/2 18.75 25 21.37 114
1/2 1/(1/2) 2/2 9.38 11 9.40 100
2/2 — 1/1 1.56 0 0.00 0*
2/2 — 1/2 3.13 0 0.00 0*
2/2 — 2/2 1.56 0 0.00 0*
2/2 1/(1/2) 1/1 4.69 8 6.84 146
2/2 1/(1/2) 1/2 9.38 8 6.84 73
2/2 1/(1/2) 2/2 4.69 6 5.13 109
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Figure 3. Survival of low-TF mice with different levels of FXI. Low-TF;FXI1/1,
low-TF;FXI1/2, and low-TF;FXI2/2 mice were assessed in a 6-month survival study.
As expected, 27% (3 of 11) of low-TF;FXI1/1 mice died by 6 months with evidence
of pulmonary hemorrhage. By comparison 10% (2 of 21) of low-TF;FXI1/2 and 25%
(3 of 12) of low-TF;FXI2/2 mice died by 6 months with evidence of pulmonary
hemorrhage. No significant difference in survival was observed between groups.
P . .05, log-rank test.
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activation of FXI both contribute to thrombin generation. However,
it is unclear whether these amplificatory pathways also contribute
to thrombin generation and hemostasis in mice.
In the present study, a deficiency in FIX resulted in a modest, but
significant, impairment in thrombin generation in mouse PPP at
a low, but not a high, initiating dose of TF. In contrast, no defect in
TF-initiated thrombin generation was observed in FXI-deficient
mouse PPP at this same low initiating dose of TF. Inhibition of
exogenous contact activation by the FXIIa inhibitor CTI at the time of
blood collection failed to reveal a contribution of FXI to TF-initiated
thrombin generation in PPP. Platelets have been identified as an
important physiologic surface for the activation of FXI by thrombin.35-37
TF-initiated thrombin generation, however, was unchanged in FXI-
deficient PRP. These data support the involvement of FIX, but not
FXI, in TF-initiated thrombin generation in mouse plasma. It is
interesting to note that in murine PPP the contribution of FIX to TF-
initiated thrombin generation was observed only at 0.05 pM of
TF, whereas in human PPP, impaired thrombin generation was
observed in FIX-deficient plasma at doses as high as 1 pM. This
result suggests that thrombin generation in humans may have
a greater dependence on FIX than in mice.
Given the similarity in the components and general mechanism of
the hemostatic systems in humans and mice, it is somewhat
surprising that FXI does not seem to serve a similar role in the
amplification of coagulation in these 2 mammals. Interestingly, it
was recently demonstrated that, unlike humans, most of the FXI
in mice is localized to the vascular surface through binding to
glycosaminoglycans, owing to an additional cluster of basic residues
on the Apple 4 domain of mouse FXI.50 This process leads to three-
to four-fold lower levels of circulating FXI in mice compared to
humans.
To confirm the ability of the TF-FVIIa complex to activate murine FIX
in vivo, dabigatran-anticoagulated mice were injected with exoge-
nous TF, and FIXa generation was determined by measurement of
plasma levels of FIXa-AT complexes. Injection of TF into wild-type
mice resulted in generation of significant levels of FIXa. This finding
was also replicated in FXI2/2 mice, which eliminated the notion of
any contribution of the thrombin-FXI pathway to the observed
generation of FIXa. This approach provides the first direct evidence
of a functional Josso loop in mice.
Having demonstrated the ability of the TF-FVIIa complex to activate
FIX in vivo in mice, we used a complementary genetic approach to
investigate the contribution of TF-FVIIa–mediated activation of FIX
to murine embryonic development and hemostasis. Mice were
crossed to generate offspring in which expression of a low level of
TF was combined with a complete deficiency of FIX. Surprisingly,
the expected number of male low-TF;FIX2/y embryos was observed
at E14.5, indicating that these embryos survived the E9.5 to 10.5
period associated with the death of mTF2/2 embryos.21-23 Birth
presents a strong hemostatic challenge as pups are squeezed
through the birth canal. Mice with a complete absence of different
components of the extrinsic (FVII) and common (FV, FX, and
prothrombin) pathways exhibit a high rate of death at birth and in the
immediate postnatal period.24-27 Some of these pups lacking key
coagulation factors appear to die of acute abdominal hemorrhage
after birth and appear pale rather than pink, with dark abdomens
due to blood pooling.24-27 Consistent with this phenotype, 2 of 5
(40%) of the low-TF;FIX2/y male mice died after birth, and 1 pup
was pale with a dark abdomen, consistent with death due to an
acute abdominal hemorrhage. In addition, 1 of 6 (17%) of the low-TF
male mice also died at birth, which was likely caused by a hemostatic
defect.
Low-TF mice backcrossed 7 generations to a C57BL/BJ back-
ground demonstrate a spontaneous hemostatic defect that results
in the death of 40% to 60% of mice by 6 months of age, primarily as
a result of spontaneous hemorrhage in the lung.38,39 In contrast,
FIX2/2 mice do not exhibit a spontaneous hemostatic defect, but
have increased bleeding upon challenge, such as a tail transection,
despite the presence of normal levels of TF. The postnatal lethality
associated with low TF;FIX2/y mice, therefore, represents a marked
exacerbation of the phenotype observed in either low-TF mice or
FIX-deficient mice. Importantly, the data suggest that FIX is
essential for the survival of low-TF mice during the trauma of birth
and in the immediate postnatal period.
To evaluate the contribution of thrombin-mediated activation of FXI,
attempts were made to generate low-TF mice lacking FXI. Low-TF;
FXI2/2 mice were generated at the expected frequency at wean
from multiple breedings involving both FXI1/2 and FXI2/2 dams, in
contrast to the attempts to generate low-TF;FIX2/y mice. Moreover,
the survival of low-TF;FXI2/2mice was not different from that of low-
TF;FXI1/2 or low-TF;FXI1/1 mice between wean and 6 months of
age. This result differs from the reduced survival of low-TF;PAR42/2
mice during the same period.39 The results from this genetic
approach suggest that FIX, but not FXI, contributes to thrombin
generation and hemostasis under conditions of reduced TF in mice.
During the generation of low-TF;FXI2/2 mice, several pregnant
dams died during late gestation. Unexpectedly, in pregnant dams
that died, several of the placentas from low-TF;FXI2/2 embryos
were found to have large maternal blood pools. Previous studies
have demonstrated that placentas from low-TF offspring contain
Table 3. Observed low-TF;FXI
2/2
offspring at weaning from additional breedings and death of females
Breeding type Expected, % Dam FXI genotype Death/pregnancy, n/n (%)
Survived Died
n/N at P21 (litters) Observed, % n/N at E13-15.5 (litters) Observed, %
1 4.69 1/2 2/23 (9) — — — —
2 10.26 1/2 2/5 (40) 1/25 (3) 4.0 4/14 (2)* 29.0
3 10.26 1/2 2/10 (20) 3/40 (6) 7.5 7/19 (2)* 37.0
4 10.26 2/2 2/6 (33) 2/19 (3) 10.5 2/7 (1) 29.0
5 20.52 2/2 3/10 (30) 3/22 (7) 13.6 6/17 (3) 35.3
*P , .05, difference in observed frequency of mTF2/2;hTF1/(1/2);FXI2/2 in surviving mothers vs dead mothers assessed by 2-tailed Fisher’s exact test.
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small maternal blood pools in the labyrinth layer.31 It is important to
note that, over a 20-year period, our group has not observed rupture
of placentas from low-TF embryos or death of pregnant mTF1/2
dams. No defect was observed in placentas from FXI2/2 offspring,
in which TF levels were normal, suggesting that a role of FXI in the
placenta is revealed only under conditions of low TF.
The death of the pregnant dams appeared to be related to the
rupture of low-TF;FXI2/2 placentas and subsequent uterine hemor-
rhage. Both FXI1/2 and FXI2/2 dams carrying low-TF;FXI2/2
embryos died during mid- to late gestation, suggesting that
embryonic, but not maternal, FXI limits the size of the placental






































































































Figure 4. Analysis of the contribution of FIX and FXI to placental blood pooling under conditions of low TF. (A) Representative images of placentas from 2 dams
from breeding 3 (top row) and 4 (bottom row), each showing a large blood pool in a low-TF;FXI2/2 placenta. Genotypes have been abbreviated to FXI1/2 (mTF1/2;hTF1/(1/2);
FXI1/2), FXI2/2 (mTF1/1;hTF1/(1/2);FXI2/2), low TF;FXI1/2 (mTF2/2;hTF1/(1/2);FXI1/2), and low TF;FXI2/2 (mTF2/2;hTF1/(1/2);FXI2/2). Blood pools are indicated by arrow-
heads or asterisks in placentas of E14.5 sections stained with hematoxylin and eosin. (B) The percentage of placental area occupied by maternal blood pools in placentas of
different genotypes was quantified at E13.5-E15.5 (n 5 4-17 per group). Filled circles indicate ruptured placentas. A significant increase in the percentage area occupied by
blood pools was observed in low-TF;FXI2/2 placentas compared with low-TF;FXI1/1 placentas. *P , .01, Kruskal-Wallis with post hoc Dunn’s tests; low TF;FIX1/y;FXI1/1
(LTF) vs low TF;FXI2/2. Data represented as individual values with median. (C) F9, F11, and F12 gene expression in the placenta at E14.5 was assessed by quantitative
polymerase chain reaction and expressed relative to expression of these genes in the liver. Data are the mean 6 SD. **P , .0001 unpaired Student t test (liver vs placenta).
(D) Representative western blots of TFPI, pro-HGF, and b-actin in tissue lysates from FXI1/1 and FXI2/2 placentas. Densitometric analysis of TFPI (E) and pro-HGF (F) in
FXI2/2 placentas and FXI1/1 controls (n 5 8 per group) normalized against b actin expression. Data are presented as individual values with the median. ***P , .01;
****P , .05, Mann-Whitney U test.
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of death of dams was observed as the expected frequency of low-TF;
FXI2/2 embryos increased in different breedings. In addition, death
of the pregnant dams in each of 5 breedings was associated with
the percentage of low-TF;FXI2/2 embryos carried by the dam. Indeed,
pregnant dams that died had a significantly higher percentage of
low-TF;FXI2/2 embryos than did dams that survived. Interestingly, the
murine placenta was found to express high levels of F11 mRNA, but
not of F9 or F12 mRNA, which suggests a specific role for FXI in the
murine placenta. In contrast, FXI is not expressed in human placenta.51
These contrasting findings provide evidence of another potential
species-specific difference in FXI biology between humans and
mice. It is possible that FXI expression in the mouse placenta serves
as an adaptive response to the reduced levels of circulating FXI.50
We have previously shown that placentas of low-TF embryos contain
blood pools.31 Maternal lacunae are separated by a barrier formed of
labyrinth trophoblast cells. Ultrastructural analysis of low-TF placen-
tas revealed a reduction in the number of contacts between
trophoblasts and a thinning of the barrier spanning the blood space
between adjacent trabeculae.31 This mechanism appears to be the
one underlying the coalescence of maternal lacunae and formation
of blood pools. It was unclear whether the primary defect in low-TF
placentas was hemostatic or structural. It is notable that there is also
a reduction in contacts between mesoderm and endoderm in the
yolk sac of TF2/2 embryos at E9.5.21 Interestingly, blood pools in
low-TF placentas were reduced by concomitant deletion of TFPI,
presumably because of increased local thrombin generation.38
It is possible that FXI contributes to thrombin generation in the
placenta. It has recently been shown that human FXI can bypass FIX
and restore hemostasis in FIX2/2 mice.17 Indeed, 2 studies have
shown that FXIa can activate FV, FVIII, and FX.17,52 High levels of
FXI in the placenta may drive a similar pathway that enhances local
thrombin generation. A deficiency of FXI would further reduce
thrombin levels under low-TF conditions and could contribute to the
observed increase in maternal blood pools in placentas from low-
TF;FXI2/2 embryos. In addition, it is possible that levels of TF are
lower in the placenta than in other tissues, making this tissue more
dependent on thrombin-mediated activation of FXI. Interestingly,
FXIa has also been shown to proteolytically inactivate TFPI.40 It is
possible that loss of FXI in the placenta leads to increased levels of
TFPI that further decrease FXa and thrombin generation in low-TF
placentas. However, analysis of placentas from FXI1/1 and FXI2/2
embryos revealed that loss of FXI resulted in a paradoxical decrease
in TFPI expression that would not explain the observed phenotype.
An alternative explanation for the increase in blood pooling in low-
TF placentas lacking FXI is that FXIa regulates factors required for
placenta development. For instance, FXIa can also serve as
a noncanonical activator of pro-HGF to active HGF.41 HGF has
been found to serve as an important regulator of placental
development. Deletion of HGF severely impaired placental devel-
opment between E13.5 and E15.5 resulting in the death of the
embryos.53,54 This is the same period during which blood pooling
was observed in low-TF and low-TF;FXI2/2 placentas. HGF2/2
placentas had significantly reduced numbers of labyrinth tropho-
blast cells with poorly developed maternal lacunae.53 Importantly,
significantly higher levels of pro-HGF were observed in FXI2/2
placentas, suggesting that FXIa could function as an important
activator of HGF during placental development. A reduction in HGF
caused by an absence of FXI may explain the observed increase in
blood pooling in low-TF placentas.
In summary, in this study, the ability of the TF-FVIIa complex to
activate FIX in vivo was confirmed. Furthermore, under conditions
of low TF, a complete deficiency in FIX was found to result in
postnatal death of mice. This finding is consistent with a critical
function for TF-FVIIa–mediated activation of FIX in thrombin generation.
In contrast, under conditions of low TF, a complete deficiency in FXI
was compatible with murine survival. However, under conditions of low
TF, FXI, but not FIX, appeared to be essential for preventing expansion
of placental blood pools, supporting a tissue-specific requirement for
FXI under conditions of low TF in mice.
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